[go: up one dir, main page]

IL133070A0 - Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses - Google Patents

Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Info

Publication number
IL133070A0
IL133070A0 IL13307098A IL13307098A IL133070A0 IL 133070 A0 IL133070 A0 IL 133070A0 IL 13307098 A IL13307098 A IL 13307098A IL 13307098 A IL13307098 A IL 13307098A IL 133070 A0 IL133070 A0 IL 133070A0
Authority
IL
Israel
Prior art keywords
adaptive
counter
composition
immune responses
graft rejection
Prior art date
Application number
IL13307098A
Original Assignee
Us Navy
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Navy, Wisconsin Alumni Res Found filed Critical Us Navy
Publication of IL133070A0 publication Critical patent/IL133070A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL13307098A 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses IL133070A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4938997P 1997-06-11 1997-06-11
PCT/US1998/011910 WO1998056417A1 (en) 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Publications (1)

Publication Number Publication Date
IL133070A0 true IL133070A0 (en) 2001-03-19

Family

ID=21959563

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13307098A IL133070A0 (en) 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Country Status (6)

Country Link
EP (1) EP1009432A4 (en)
JP (1) JP2002504120A (en)
AU (1) AU748533B2 (en)
CA (1) CA2291338A1 (en)
IL (1) IL133070A0 (en)
WO (1) WO1998056417A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
EP1141240A4 (en) * 1998-12-29 2003-09-10 Univ Vermont USE OF THE CD40 COUPLING TO MODIFY THE USE OF THE T-CELL RECEPTOR
PT1144010E (en) * 1999-01-08 2007-07-20 Wisconsin Alumni Res Found Prevention of chronic graft rejection by a combination of immunotoxins and costimulation blockers
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2411962A1 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
TWI322153B (en) 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
CA2436180C (en) * 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
DK1397153T3 (en) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Method for protecting allogeneic islet cell graft using soluble CTLA4 mutant molecules
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
CA3104807A1 (en) 2018-06-22 2019-12-26 Junten Bio Co., Ltd. Composition for eliciting infectious immunological tolerance
AU2019288683A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
CA3104783A1 (en) 2018-06-22 2019-12-26 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
JP2025038261A (en) * 2022-02-08 2025-03-19 学校法人順天堂 Allogeneic transplantation method and method for suppressing rejection reaction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2191733A1 (en) * 1994-06-07 1995-12-21 Daniel A. Vallera Methods for inhibiting antigen specific t cell responses
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
WO1998056417A1 (en) 1998-12-17
JP2002504120A (en) 2002-02-05
AU748533B2 (en) 2002-06-06
AU7956798A (en) 1998-12-30
CA2291338A1 (en) 1998-12-17
EP1009432A1 (en) 2000-06-21
EP1009432A4 (en) 2004-07-07

Similar Documents

Publication Publication Date Title
IL133070A0 (en) Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
IL118589A0 (en) Compositions and method for improving autologous fat grafting
IL115551A0 (en) Intraluminal graft and method for insertion thereof
OA09633A (en) Tissue graft composition and method
HUP0000302A3 (en) Ob fusion protein compositions and methods
ZA964733B (en) Ob protein compositions and methods
EP0833615A4 (en) Nutritional and/or dietary composition and method of using the same
ZA958028B (en) Compositions and methods for treatig mast-cell mediated conditions
GB2298713B (en) Method and composition
PL321935A1 (en) Electroplating compositions and methods
AU6237596A (en) Angiosurgical device and vascular graft and vascular annulusfor vessel-vascular graft binding
ZA989399B (en) Method and composition
EP0555413A4 (en) Methods and compositions for suppressing allograft rejection in mammals
EP0873071A4 (en) Organizer rack component and method of using same
GB9624501D0 (en) Insecticial compositions and method
PL327853A1 (en) Materials and methods related to exodus chemokin
GB9508546D0 (en) Method and composition
GB9419087D0 (en) Method and composition
AU6648498A (en) Methods and compositions using interleukin-13 for enhancing immune responses
GB9026896D0 (en) Method and composition
GB9619261D0 (en) Pesticidal composition and method
ZA919566B (en) Jumper switch means and method
GB9601656D0 (en) Novel composition and method
ZA946995B (en) Specimens and their making methods
GB9025513D0 (en) Incendiary method and composition